Literature DB >> 24928089

Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera.

Natalia Simionescu1, Loredan S Niculescu, Gabriela M Sanda, Denisa Margina, Anca V Sima.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNA sequences that regulate gene expression post-transcriptionally by translation inhibition or mRNA degradation. The aim of the present study was to analyze serum miRNAs modulated by hyperlipidemia and/or hyperglycemia and to correlate them with biochemical parameters within lipid metabolism. Five selected circulating miRNAs (miR-125a-5p, miR-146a, miR-10a, miR-21 and miR-33a) were individually analyzed by TaqMan miRNA assays along with lipid and inflammation parameters in sera from 20 hyperlipidemic (HL) and/or hyperglycemic (HG) patients, and compared with data from five normolipidemic/normoglycemic subjects. Results showed: (1) the levels of all the analyzed circulating miRNA were increased in HL sera and correlated positively with sera's lipid and inflammatory parameters; (2) circulating miR-125a-5p and miR-146a levels were increased in HG and/or HL sera; (3) all selected miRNAs were detected in α-lipoprotein fraction from sera, and miR-33a was also present in β-lipoprotein fraction; (4) miRNA concentrations were increased in the α-lipoprotein fraction from HL sera. These data show a statistically significant correlation of the analyzed miRNA with increased lipids, specifically with α- and β-lipoproteins, and CRP and IL-1β levels in HL and/or HG sera, suggesting a contribution of these miRNAs to the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24928089     DOI: 10.1007/s11033-014-3449-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

Review 1.  The role of microRNAs in arterial remodelling.

Authors:  M Nazari-Jahantigh; Y Wei; A Schober
Journal:  Thromb Haemost       Date:  2012-02-28       Impact factor: 5.249

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

4.  MiR-33 contributes to the regulation of cholesterol homeostasis.

Authors:  Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando
Journal:  Science       Date:  2010-05-13       Impact factor: 47.728

5.  MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4.

Authors:  Ke Yang; Yu Song He; Xiao Qun Wang; Lin Lu; Qiu Jing Chen; Jing Liu; Zhen Sun; Wei Feng Shen
Journal:  FEBS Lett       Date:  2011-02-15       Impact factor: 4.124

6.  Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes.

Authors:  M Balasubramanyam; S Aravind; K Gokulakrishnan; P Prabu; C Sathishkumar; H Ranjani; V Mohan
Journal:  Mol Cell Biochem       Date:  2011-01-20       Impact factor: 3.396

Review 7.  MicroRNAs and cardiovascular diseases.

Authors:  Koh Ono; Yasuhide Kuwabara; Jiahuai Han
Journal:  FEBS J       Date:  2011-03-30       Impact factor: 5.542

8.  Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia.

Authors:  Kyriakos E Kypreos; Ko W van Dijk; Louis M Havekes; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2004-12-02       Impact factor: 5.157

9.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

10.  Induction of thoracic aortic remodeling by endothelial-specific deletion of microRNA-21 in mice.

Authors:  Xing-Yi Zhang; Bao-Rong Shen; Yu-Cheng Zhang; Xue-Jiao Wan; Qing-Ping Yao; Guang-Liang Wu; Ji-Yao Wang; Si-Guo Chen; Zhi-Qiang Yan; Zong-Lai Jiang
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more
  16 in total

1.  The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression.

Authors:  M Sidorkiewicz; M Grek; B Jozwiak; A Krol; A Piekarska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-25       Impact factor: 3.267

2.  microRNA-146a-5p association with the cardiometabolic disease risk factor TMAO.

Authors:  Alisha R Coffey; Matt Kanke; Tangi L Smallwood; Jody Albright; Wendy Pitman; Raad Z Gharaibeh; Kunjie Hua; Erik Gertz; Sudha B Biddinger; Ryan E Temel; Daniel Pomp; Praveen Sethupathy; Brian J Bennett
Journal:  Physiol Genomics       Date:  2019-01-11       Impact factor: 3.107

Review 3.  The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application.

Authors:  Yu Xiang; Li Mao; Mei-Ling Zuo; Gui-Lin Song; Li-Ming Tan; Zhong-Bao Yang
Journal:  Mediators Inflamm       Date:  2022-06-17       Impact factor: 4.529

4.  Dietary Improvement during Lactation Normalizes miR-26a, miR-222 and miR-484 Levels in the Mammary Gland, but Not in Milk, of Diet-Induced Obese Rats.

Authors:  Catalina A Pomar; Pedro Castillo; Andreu Palou; Mariona Palou; Catalina Picó
Journal:  Biomedicines       Date:  2022-05-31

5.  Inhibition of miR-486 and miR-92a decreases liver and plasma cholesterol levels by modulating lipid-related genes in hyperlipidemic hamsters.

Authors:  Loredan S Niculescu; Natalia Simionescu; Elena V Fuior; Camelia S Stancu; Mihaela G Carnuta; Madalina D Dulceanu; Mina Raileanu; Emanuel Dragan; Anca V Sima
Journal:  Mol Biol Rep       Date:  2018-05-03       Impact factor: 2.316

6.  Expression profiling of preadipocyte microRNAs by deep sequencing on chicken lines divergently selected for abdominal fatness.

Authors:  Weishi Wang; Zhi-Qiang Du; Bohan Cheng; Yuxiang Wang; Jing Yao; Yumao Li; Zhiping Cao; Peng Luan; Ning Wang; Hui Li
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

7.  MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.

Authors:  Alessandra Tessitore; Germana Cicciarelli; Filippo Del Vecchio; Agata Gaggiano; Daniela Verzella; Mariafausta Fischietti; Valentina Mastroiaco; Antonella Vetuschi; Roberta Sferra; Remo Barnabei; Daria Capece; Francesca Zazzeroni; Edoardo Alesse
Journal:  BMC Cancer       Date:  2016-01-05       Impact factor: 4.430

8.  MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients.

Authors:  Loredan S Niculescu; Natalia Simionescu; Gabriela M Sanda; Mihaela G Carnuta; Camelia S Stancu; Andreea C Popescu; Mihaela R Popescu; Adelina Vlad; Doina R Dimulescu; Maya Simionescu; Anca V Sima
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

9.  Hyperglycemia Determines Increased Specific MicroRNAs Levels in Sera and HDL of Acute Coronary Syndrome Patients and Stimulates MicroRNAs Production in Human Macrophages.

Authors:  Natalia Simionescu; Loredan S Niculescu; Mihaela G Carnuta; Gabriela M Sanda; Camelia S Stancu; Andreea C Popescu; Mihaela R Popescu; Adelina Vlad; Doina R Dimulescu; Maya Simionescu; Anca V Sima
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

Review 10.  Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Marta B Afonso; Pedro M Rodrigues; André L Simão; Rui E Castro
Journal:  J Clin Med       Date:  2016-03-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.